Answers are grounded in this paper and cite their sources.
Background People living with HIV (PLWH) may continue to experience interacting mucocutaneous lesions, pain, pruritus, oral infection, impaired healing, constitutional symptoms and reduced quality of life despite effective antiretroviral therapy (ART). Light-based interventions can modify local pathology and immune signaling, but their clinical and mechanistic evidence is dispersed across dermatology, dentistry, infectious disease, oncology and apheresis. Methods This scoping review was structured using JBI guidance and reported in accordance with PRISMA-ScR. PubMed, Web of Science, Embase, CINAHL, the Cochrane Library, CNKI, Wanfang, VIP and SinoMed were searched from inception to 9 August 2026. Clinical sources were charted by population, modality, optical parameters, symptom domain, efficacy, safety, immune or virological outcomes and treatment burden. Design-specific appraisal used RoB 2 for randomized trials, ROBINS-I for non-randomized comparative intervention studies and JBI checklists for other eligible designs. Clinical evidence directly obtained in PLWH was synthesized separately from contextual photobiology and hypothesis-generating mechanistic links. Results Fifty-five evidence sources, 21 Chinese and 34 English, represented 54 unique cohorts. Evidence clustered in anogenital HPV-related disease, dermatologic disease and ultraviolet safety, oral conditions, Kaposi sarcoma and systemic or psychological interventions. Across modalities, randomized evidence was mostly judged as having some concerns, non-randomized comparative studies commonly had moderate-to-serious risk of bias, and uncontrolled or historical reports had substantial methodological limitations. No modality was supported by high-certainty clinical evidence. ALA-based photodynamic therapy (PDT) had the most concentrated, but still low-certainty, support for local lesion control in anogenital disease. Oral antimicrobial PDT, photobiomodulation and UVB had narrower or very-low-certainty support. A contemporary sham-controlled vascular-PBM trial did not show virological or immunological superiority. The molecular synthesis distinguishes direct PLWH observations from contextual pathways and hypothesis-generating links. Conclusion Light-based therapies should be positioned as adjunctive, symptom-directed interventions. ALA-PDT for anogenital HPV-related disease has the strongest relative signal, but confidence remains low because of risk of bias, heterogeneity and limited follow-up. Oral aPDT may be considered adjunctive, whereas PBM, lesion-directed Kaposi therapy, extracorporeal photopheresis and bright-light therapy remain experimental or very low certainty in PLWH. Current evidence does not support vascular PBM for systemic immune restoration or virological control. UVB requires an explicit local HIV-transcription safety boundary. No evidence supports HIV eradication. Open science framework record: https://doi.org/10.17605/OSF.IO/WNX84 .
No takes yet. Share an insight, caveat, or question.
Su et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: